摘要
目的:研究载药栓塞微球-经导管肝动脉化疗栓塞术(DEB-TACE)介入治疗肝癌的临床效果。方法:选取2021年12月—2022年12月南京市高淳人民医院收治的69例肝癌患者,根据治疗方法将30例接受DEB-TACE介入治疗的患者纳入观察组,39例接受传统TACE治疗的患者纳入对照组,比较两组患者治疗前、治疗1个周期后肿瘤标志物,全身免疫炎症指数,血清甲胎蛋白(AFP)、血管内皮生长因子(VEGF)水平及术后不良事件发生率。结果:治疗1个周期后,两组癌胚抗原(CEA)、糖类抗原125(CA125)、血清铁蛋白(SF)水平较治疗前均显著下降,差异有统计学意义(P<0.05),但两组组间比较,差异无统计学意义(P>0.05)。治疗1个周期后,两组全身免疫炎症指数均下降,且观察组全身免疫炎症指数低于对照组,差异有统计学意义(P<0.05);治疗1个周期后,两组血清AFP、VEGF水平均显著下降,且观察组血清AFP、VEGF水平显著低于对照组,差异有统计学意义(P<0.05)。观察组术后发生不良事件发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:DEB-TACE、传统TACE介入治疗均能够有效地调节肝癌患者肿瘤标志物水平,但DEB-TACE介入治疗全身免疫炎症反应更轻,可降低血清AFP和VEGF水平,不良事件发生风险更低。
Objective:To study the effects of drug loaded embolization microspheres-transcatheter hepatic artery chemoembolization(DEB-TACE)in patients with liver cancer.Method:A total of 69 liver cancer patients admitted to Nanjing Gaochun People's Hospital from December 2021 to December 2022 were selected.According to the treatment method,30 patients who received DEB-TACE intervention treatment were included in the observation group,and 39 patients who received traditional TACE treatment were included in the control group.The tumor markers,systemic immune inflammation index,serum alpha fetoprotein(AFP),vascular endothelial growth factor(VEGF)levels before and after 1 cycle of treatment,and incidence of postoperative adverse events were compared between the two groups.Result:After 1 cycle of treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and serum ferritin(SF)in the two groups were significantly lower than those before treatment,the differences were statistically significant(P<0.05),but there was no significant difference between the two groups(P>0.05).After 1 cycle of treatment,the systemic immune inflammation index of both groups decreased,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).After 1 cycle of treatment,the levels of serum AFP and VEGF in both groups were significantly decreased,and the levels of serum AFP and VEGF in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of postoperative adverse events in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Both DEB-TACE and traditional TACE intervention therapy can effectively regulate the levels of tumor markers in liver cancer patients.However,DEB-TACE intervention therapy has a lighter systemic immune inflammatory response and lower serum AFP and VEGF levels,and has a lower
作者
王韬
WANG Tao(Nanjing Gaochun People's Hospital,Nanjing 211300,China)
出处
《中外医学研究》
2023年第29期36-41,共6页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
肝癌
载药栓塞微球-经导管肝动脉化疗栓塞术
肿瘤标志物
全身免疫炎症指数
甲胎蛋白
血管内皮生长因子
Liver cancer
Drug loaded embolization microspheres-transcatheter hepatic artery chemoembolization
Tumor markers
Systemic immune inflammation index
Alpha fetoprotein
Vascular endothelial growth factor
